Quipt Home Medical (QIPT) Stock Price, News & Analysis

Company Overview

Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The company's services consist of Daily & Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea & PAP Treatment.

Key Stats

• Today's Range: C$3.12 to C$3.25
• 50-Day Range: C$2.37 to C$3.20
• 52-Week Range: C$1.90 to C$4.99
• Volume: 6,705 shs
• Average Volume: 27,152 shs
• Market Capitalization: C$94.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: C$7.50
• Consensus Rating: Buy

QIPT Stock Analysis - Frequently Asked Questions

How have QIPT shares performed this year?

Quipt Home Medical's stock was trading at C$4.38 at the beginning of 2025. Since then, QIPT shares have decreased by 28.8% and is now trading at C$3.12.

How do I buy shares of Quipt Home Medical?

Shares of QIPT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Quipt Home Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Quipt Home Medical investors own include AbCellera Biologics (ABCL), Avino Silver & Gold Mines (ASM), ASML (ASML), Broadcom (AVGO), Booking (BKNG) and Boralex (BLX).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: Healthcare
• Current Symbol: TSE:QIPT
• CIK: N/A
• Web: quipthomemedical.com
• Phone: 859-878-2220
• Fax: N/A
• Employees: 800
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Quipt Home Medical: C$7.50
• High Price Target: C$7.50
• Low Price Target: C$7.50
• Potential Upside/Downside: +140.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): C($0.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 45.58
• P/E Growth: N/A
• Net Income: -C$5.16 million
• Net Margins: -3.00%
• Pretax Margin: N/A
• Return on Equity: -6.70%
• Return on Assets: 1.15%

Debt

• Debt-to-Equity Ratio: 94.74
• Current Ratio: 1.22
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: C$171.98 million
• Price / Sales: 0.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: C$2.49 per share
• Price / Book: 1.25

Miscellaneous

• Outstanding Shares: 30,299,217
• Free Float: N/A
• Market Cap: C$94.53 million
• Optionable: Not Optionable
• Beta: 1.01